Truscreen Priority Allocation of $1 Million Closed

NZX Announcement

4 June 2020
Truscreen Limited priority allocation of $1 million closed
Truscreen is pleased to announce that its previously announced offer to raise $1,000,000 through a
priority allocation to an NZX market participant closed on 3 June 2020, fully subscribed.
TRU expects that the new shares to be issued pursuant to the priority allocation will be allotted, and
holder statements sent out to shareholders on or about Friday 5 June 2020.
Auckland based capital markets advisory firm CM Partners advised TRU on the capital raising initiative.

- ENDS -


For more information, visit www.truscreen.com or contact:

TruScreen
Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com


Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which
offers the latest technology in cervical screening,
providing real-time, accurate detection of pre-
cancerous and cancerous cervical cells to help improve
the health and well-being of women around the world.
TruScreen’s real-time cervical cancer technology
utilises a digital wand which is placed on the surface of
the cervix to measure electrical and optical signals from
the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous
change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing
issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and
the need for supporting laboratory infrastructures. As such, TruScreen’s target market is low-
and middle-income countries where no large-scale cervical cancer screening programs and
infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical
cancer screening device is CE-marked and certified for use throughout Europe and CFDA-
approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-
video/